15价肺炎球菌结合疫苗

Search documents
重组大动作!又一家汽车央企来了 | 盘后公告精选
Jin Shi Shu Ju· 2025-06-06 01:47
Group 1 - Changan Automobile's indirect controlling shareholder will change to a newly established central enterprise after the separation of its automotive business from the Equipment Group, with no significant impact on the company's operations [1] - Zhifei Biological's 15-valent pneumococcal conjugate vaccine application for production registration has been accepted, which could enhance the company's market position and competitiveness [2] - Wanda Film is launching a shareholder return activity, allowing eligible shareholders to purchase movie ticket packages at a significantly reduced price [3] Group 2 - InSail Group plans to acquire 80% of the equity of Zhizhe Brand through a combination of issuing shares and cash payment [4] - Muyuan Foods reported May sales of 6.406 million pigs, with a revenue of 12.258 billion yuan, reflecting a year-on-year increase of 26.93% [6] - Shenzhou Cell plans to raise up to 900 million yuan through a private placement to supplement working capital [7] Group 3 - China Oil Engineering's subsidiary received a contract worth approximately 2.94 billion USD for a gas pipeline project in Iraq [8] - Dongfeng Motor reported a 31.26% year-on-year decrease in May sales of new energy vehicles, totaling 1,270 units [14] - Huazhong Pharmaceutical's subsidiary received a drug registration certificate for a new antidepressant, which has been in development since 2021 [24] Group 4 - Juhua Technology won a bid for a 197 million yuan project from the State Grid [27] - Zhaojin Mining announced plans to acquire a controlling stake in Zhixue Cloud, which may constitute a significant asset restructuring [26] - Mypo Medical intends to acquire 100% of Yijie Medical's equity, expanding its capabilities in the interventional field [13]
智飞生物:15价肺炎球菌结合疫苗申请生产注册获受理
news flash· 2025-06-05 10:31
智飞生物(300122)公告,全资子公司智飞绿竹研发的15价肺炎球菌结合疫苗申请生产注册获得国家药 品监督管理局出具的《受理通知书》。该疫苗为预防用生物制品,涵盖亚洲地区检出率最高的15种血清 型,用于预防相关血清型肺炎球菌所致疾病。截至公告披露日,尚无其他15价肺炎球菌结合疫苗获批上 市。15价肺炎球菌结合疫苗申请生产注册获得受理符合疫苗多联多价研究方向,若项目进展顺利,将与 公司已经上市的23价肺炎球菌多糖疫苗、现处于I/II期临床试验阶段的26价肺炎球菌结合疫苗形成协同 效应,进一步夯实公司肺炎疫苗矩阵,强化公司的市场地位,提升公司竞争力。 ...